World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
103
Citations
54893
World Ranking
7205
National Ranking
3780

Michael A. Davies publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael A. Davies sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 512 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael A. Davies D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael A. Davies sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 103 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael A. Davies is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans across several intersecting fields within medicine and biomedical science, especially focusing on oncology and molecular biology.

Their extensive body of work includes a total of 387 publications in Medicine and 177 in Biochemistry, Genetics, and Molecular Biology. Key subfields include Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology, and Biomedical Engineering, reflecting a multidisciplinary approach to cancer research and treatment.

Davies has contributed significantly to research in the areas of cancer immunotherapy and biomarkers, melanoma and MAPK pathways, brain metastases and treatment, CAR-T cell therapy research, immunotherapy and immune responses, cutaneous melanoma detection and management, and nanoplatforms for cancer theranostics.

Frequent co-authors collaborating with Davies include:

  • Jennifer L. McQuade
  • Adi Diab
  • Hussein A. Tawbi
  • Elizabeth M. Burton
  • Rodabe N. Amaria

Their work has been published predominantly in several scientific venues, with major contributions in:

  • Journal of Clinical Oncology (40 publications)
  • Cancer Research (30 publications)
  • Annals of Oncology (11 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (11 publications)
  • Neuro-Oncology Advances (10 publications)

Selected recent publications highlight Davies's involvement in advancing understanding of immunotherapy and melanoma treatment:

  • "B cells and tertiary lymphoid structures promote immunotherapy response", 2020, Nature
  • "Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response", 2021, Science
  • "Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)", 2021, Nature Medicine
  • "Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade", 2021, Nature Medicine
  • "Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity", 2022, Cancer Cell

Best Publications

  • Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

    V. Gopalakrishnan;V. Gopalakrishnan;C. N. Spencer;C. N. Spencer;L. Nezi;A. Reuben

  • Genomic Classification of Cutaneous Melanoma

    Rehan Akbani;Kadir C. Akdemir;B. Arman Aksoy;Monique Albert

  • A landscape of driver mutations in melanoma

    Eran Hodis;Ian R. Watson;Ian R. Watson;Gregory V. Kryukov;Gregory V. Kryukov;Gregory V. Kryukov;Stefan T. Arold

  • B cells and tertiary lymphoid structures promote immunotherapy response

    Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang

  • Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

    Weiyi Peng;Jie Qing Chen;Chengwen Liu;Shruti Malu

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

    Pei Ling Chen;Whijae Roh;Alexandre Reuben;Zachary A. Cooper

  • NRAS mutation status is an independent prognostic factor in metastatic melanoma.

    John A. Jakob;Roland L. Bassett;Chaan S. Ng;Jonathan L. Curry

  • Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

    Alexander M. Menzies;Alexander M. Menzies;D. B. Johnson;S. Ramanujam;V. G. Atkinson

  • Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance

    Whijae Roh;Pei Ling Chen;Alexandre Reuben;Christine N. Spencer

  • Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

    Rodabe N. Amaria;Sangeetha M. Reddy;Hussein A. Tawbi;Michael A. Davies

  • Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial

    Michael A. Davies;Philippe Saiag;Caroline Robert;Jean Jacques Grob

  • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

    G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

  • Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

    Jennifer L. McQuade;Carrie R. Daniel;Kenneth R. Hess;Carmen Mak

  • Prognostic Factors for Survival in Melanoma Patients with Brain Metastases

    Michael A. Davies;Ping Liu;Susan McIntyre;Kevin B. Kim

  • AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

    Krishna M. Vasudevan;David A. Barbie;David A. Barbie;Michael A. Davies;Rosalia Rabinovsky

  • Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.

    Tina Cascone;Jodi A. McKenzie;Rina M. Mbofung;Simone Punt

  • Exome sequencing identifies GRIN2A as frequently mutated in melanoma

    Xiaomu Wei;Vijay Walia;Jimmy C Lin;Jamie K Teer

  • The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells

    Yiling Lu;Yue Zhen Lin;Ruth LaPushin;Bruce Cuevas

Frequent Co-Authors

Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Jeffrey E. Gershenwald
Jeffrey E. Gershenwald The University of Texas MD Anderson Cancer Center
Alexander J. Lazar
Alexander J. Lazar The University of Texas MD Anderson Cancer Center
Adi Diab
Adi Diab The University of Texas MD Anderson Cancer Center
Georgina V. Long
Georgina V. Long University of Sydney
Gordon B. Mills
Gordon B. Mills Oregon Health & Science University
Keith T. Flaherty
Keith T. Flaherty Harvard University
Victor G. Prieto
Victor G. Prieto The University of Texas MD Anderson Cancer Center
Chantale Bernatchez
Chantale Bernatchez The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways into the healthcare field can open new career opportunities, even for those who do not plan to attend traditional medical school. For example, aspiring nurses who hold a bachelor’s degree in another field can consider direct entry online MSN programs, which allow non-nurses to enter the profession quickly through accelerated online study.

Some individuals may be looking for what is the easiest nursing program to get into. Options are available that prioritize accessibility and flexibility, making it possible to pursue a nursing career without overwhelming entrance requirements.

If clinical patient care is not your ideal fit, another growing area is medical billing and coding. Many reputable institutions now offer medical coding and billing classes online with financial aid, providing a convenient route into healthcare administration roles.

Additionally, students wanting to avoid standardized tests can research nursing schools that don't require teas or hesi, making the process of starting a healthcare career even smoother. These options help make a future in healthcare more accessible to a wider range of students.

Best Scientists Citing Michael A. Davies

Trending Scientists

Recently Published Articles